Search Weight Loss Topics:


Page 4«..3456..1020..»


Nov 5

Novartis Cosentyx shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study – BioSpace

EAST HANOVER, N.J., Nov. 5, 2020 /PRNewswire/ -- Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial, which demonstrated the significant treatment response of Cosentyx (secukinumab) on synovitis (joint lining inflammation) in psoriatic arthritis (PsA) versus placebo. Synovitis was assessed using an advanced and sensitive imaging technique called Power Doppler ultrasonography (PDUS). These data are being presented at the American College of Rheumatology (ACR) All-Virtual Annual Meeting, November 5-9, 2020.

"Psoriatic arthritis can have a significant impact on a patient's joints. Joint lining inflammation, also known as synovitis, if left untreated, can cause pain to worsen, joint damage and may decrease physical function," said Dr. Maria A. D'Agostino, Professor of Rheumatology at the Catholic University of Rome. "These data are highly encouraging, showing Cosentyx can significantly reduce synovitis at Week 12 versus placebo with results seen as early as Week 1, and that ultrasound is a sensitive and objective tool to monitor joint inflammation in PsA patients."

The use of a standardized ultrasound synovitis score (GLOESS) as the primary endpoint showed objectively the significant benefit of Cosentyx versus placebo on synovitis at Week 12 with an early improvement observed from Week one. Treatment with Cosentyx also significantly improved key secondary endpoints versus placebo, including ACR20 (68% vs 34%, respectively), ACR50 (46% vs 9%, respectively) and enthesitis (mean change from baseline in Spondyloarthritis Research Consortium of Canada enthesitis index score [SPARCC] of -2.4 vs -1.7 respectively)1. The safety profile of Cosentyx through 12 weeks was consistent with previous studies1.

Novartis anticipates disclosing full 24-week data from the ongoing ULTIMATE trial at the European League Against Rheumatism (EULAR) annual meeting in 2021 and final analysis at ACR 2021.

"As a strong believer in the diagnostic and treatment monitoring benefits of ultrasound, this first large randomized double-blind placebo-controlled clinical trial in PsA with an ultrasonographic primary endpoint is incredibly exciting. The ability to use a sensitive imaging technique to assess synovitis and enthesitis in PsA represents a breakthrough in how we conceptualize treatment goals," said Dr. Catherine Bakewell of Intermountain Medical Group in Salt Lake City, UT and an investigator in the ULTIMATE study. "In addition to other measures, PDUS helps to provide earlier insight into treatment response and that patients are more effectively treated across multiple domains of this heterogeneous psoriatic disease spectrum."

PsA is a complex disease with multiple manifestations driving patient symptoms3,4. In PsA, synovitis may lead to joint damage and if left untreated, the joint damage can be irreversible5,6. In addition to reducing synovitis, Cosentyx has been proven to provide long-lasting inhibition of radiographic progression in PsA, limiting joint damage and helping to improve outcomes for patients with this debilitating condition7,8.

About Psoriatic Arthritis (PsA)PsA is estimated to affect up to 50 million people worldwide9,10. It is part of a family of life-long inflammatory diseases (spondyloarthritis) that target the joints and is closely associated with psoriasis10. Up to 40% of patients with psoriasis may develop PsA10. Symptoms of PsA include joint pain and stiffness, skin and nail psoriasis, swollen toes and fingers, persistent painful swelling of the tendons and irreversible joint damage10.

About ULTIMATE ULTIMATE is the first ongoing 52-week double-blind, placebo-controlled Phase IIIb study using ultrasound to assess time-course of response of Cosentyx on synovitis in psoriatic arthritis. The study enrolled 166 adult biologic-nave patients with active Psoriatic arthritis. Patients were randomized (1:1) to receive either secukinumab (300-mg or 150-mg according to severity of skin disease) or placebo weekly for a month with treatment starting at Week 4, followed by a once-a-month dose for the next 11 months.

The primary endpoint is the difference in mean change from baseline to Week 12 between secukinumab and placebo in Global Omeract-European League Against Rheumatism Ultrasound Synovitis Score (GLOESS). GLOESS is a standardized composite score that has shown to be sensitive to change and able to detect and score synovitis11. Secondary endpoints include ACR20, ACR50 and change in Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index from baseline to Week 12 compared with placebo.

ACR20 and ACR50 are composite measures defined as both improvement of 20% or 50% in the number of tender and number of swollen joints, and a 20% or 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, Health Assessment Questionnaire, visual analog pain scale and erythrocyte sedimentation rate or C-reactive protein12. The SPARCC enthesitis index is a validated clinical tool for evaluation of enthesitis13,14.

About Cosentyx (secukinumab)Cosentyx is the first and only fully-human biologic that directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the inflammation and development of psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS) and nr-axSpA15,16. Cosentyx has been studied clinically for more than 13 years. The medicine is backed by robust investigational evidence, including five years of clinical data supporting long-term safety and efficacy across moderate to severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)17-22,23. These data strengthen the unique position of Cosentyx as a comprehensive treatment across axial spondyloarthritis, psoriatic arthritis and psoriatic disease, supported by more than 400,000 patients treated worldwide since launch2,23,24.

IMPORTANT SAFETY INFORMATIONDo not use COSENTYX if you have had a severe allergic reaction to secukinumab or any of the other ingredients in COSENTYX. See the Medication Guide for a complete list of ingredients.

COSENTYX is a medicine that affects your immune system. COSENTYX may increase your risk of having serious side effects such as:

InfectionsCOSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections.

Before starting COSENTYX, tell your doctor if you:

After starting COSENTYX, call your doctor right away if you have any signs of infection listed above. Do not use COSENTYX if you have any signs of infection unless you are instructed to by your doctor.

Inflammatory Bowel DiseaseNew cases of inflammatory bowel disease or "flare-ups" can happen with COSENTYX, and can sometimes be serious. If you have inflammatory bowel disease (ulcerative colitis or Crohn's disease), tell your doctor if you have worsening disease symptoms during treatment with COSENTYX or develop new symptoms of stomach pain or diarrhea.

Serious Allergic ReactionsSerious allergic reactions can occur. Get emergency medical help right away if you get any of the following symptoms: feeling faint; swelling of your face, eyelids, lips, mouth, tongue, or throat; trouble breathing or throat tightness; chest tightness; or skin rash. If you have a severe allergic reaction, do not give another injection of COSENTYX.

Before starting COSENTYX, tell your doctor if you:

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of your medicines to show your doctor and pharmacist when you get a new medicine.

How should I use COSENTYX?See the detailed Instructions for Use that comes with your COSENTYX for information on how to prepare and inject a dose of COSENTYX, and how to properly throw away (dispose of) used COSENTYX Sensoready pens and prefilled syringes.

The most common side effects of COSENTYX include: cold symptoms, diarrhea, and upper respiratory infections. These are not all of the possible side effects of COSENTYX. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information, including Medication Guide.

DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisLocated in East Hanover, NJ Novartis Pharmaceuticals Corporation an affiliate of Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis employs more than 15,000 people in the United States. For more information, please visit https://www.novartis.us.

Novartis and Novartis US is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews and @NovartisUS at https://twitter.com/NovartisUS.For Novartis multimedia content, please visit https://www.novartis.com/news/media-libraryFor questions about the site or required registration, please contact media.relations@novartis.com.

References

1.

D'Agostino MA, Schett G, Lpez-Rdz A, et al. Secukinumab significantly decreased joint synovitis measured by power Doppler ultrasonography in biologic nave patients with active psoriatic arthritis: primary (12-week) results from a randomized, placebo-controlled Phase III study. Abstract presented at the American College of Rheumatology (ACR) Convergence 2020: The ACR's All-Virtual Annual Meeting.

2.

Data on file. COSENTYX access. Novartis Pharmaceuticals Corp; July 2020.

3.

Ritchin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-970.

4.

Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Rheumotol Ther. 2016;3(1):91-102.

5.

Van Kuijk A, Tak P. Synovitis in psoriatic arthritis: immunochemistry, comparisons with rheumatoid arthritis and effects of therapy. Curr Rheumatol Rep. 2011;13:353-359.

6.

Celis R, Cuervo A, Ramirez J, et al. Psoriatic synovitis: singularity and potential clinical implications. Frontiers in Medicine. 2019;6:1-7

7.

Mease P, van der Heijde D, Landew R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study Annals of the Rheumatic Diseases 2018;77:890-897.

8.

Van Der Heijde D, Mease PJ, Landewe R, et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology. 2020;59:13251334

9.

National Psoriasis Foundation. Psoriasis statistics. Available from: https://www.psoriasis.org/content/statistics. Last accessed: October 2020.

10.

Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74:423-441.

11.

D'Agostino MA, Terslev L, Aegerter P, et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: definition and development of a standardised, consensus-based scoring system. RMD Open. 2017;3:e000428.

12.

Eprovide. American College of Rheumatology 20/50/70 criteria (ACR20/50/70). Available from: https://eprovide.mapi-trust.org/instruments/american-college-of-rheumatology-20-50-70-criteria#:~:text=The%20ACR20%20is%20a%20composite,Health%20Assessment%20Questionnaire%20(HAQ)%5D%2C. Last accessed: October 2020.

13.

Maksymowych WP, Mallon C, Morrow S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis. 2009;68(6):948-953.

14.

Mease PJ, Van den Bosch F, Sieper J, Xia Y, Pangan AL, Song IH. Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. J Rheumatol. 2017 May;44(5):599-608.

15.

Novartis Europharm Limited. Cosentyx (secukinumab): Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx Last accessed: August 2019.

16.

Girolomoni G, et al. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 2012;167:717724.

17.

Data on file. CAIN457F2310 (MEASURE 2): 5 Year Report. Novartis Pharmaceuticals Corp; September 15, 2015.

18.

Data on file. Data Analysis Report: Study CAIN457A2302E1. Novartis Pharmaceuticals Corp; November 30, 2015.

19.

Data on file. CAIN457F2310 and CAIN457F2305 Summary of 5-Year Clinical Safety in (Ankylosing Spondylitis). Novartis Pharmaceuticals Corp; May 2019.

20.

Data on file. CAIN457F2312 (FUTURE 2): 5 Year- Interim Report. Novartis Pharmaceuticals Corp; May 2019.

21.

Data on file. CAIN457F2312 Data Analysis Report. Novartis Pharmaceuticals Corp; November 2008.

22.

Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data. Novartis Pharmaceuticals Corp; July 23, 2018.

23.

Cosentyx [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2020.

24.

Data on file. AIN457A2102 Clinical Study Report. Novartis Pharmaceuticals Corp; December 2008.

View original content:http://www.prnewswire.com/news-releases/novartis-cosentyx-shows-early-synovitis-reduction-in-patients-with-psoriatic-arthritis-in-first-of-its-kind-study-301166845.html

SOURCE Novartis Pharmaceuticals Corporation

See original here:
Novartis Cosentyx shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study - BioSpace


Nov 1

How to exercise to lose weight and build muscle at the same time – Daily Express

Speaking to Express.co.uk, Bulk Powders ambassador Hayley Madigan shared her top weight training tips.

She said: Weight training has a vast range of positive benefits for women, not just physically but mentally too! Weight training loads a resistance to our muscles, which allows them to rebuild stronger.

Not only does weight training improve our muscle strength, it also strengthens our bones, joints, ligaments and tendons all vital for our long-term health.

Additional to these benefits, weight training can improve heart health and blood pressure, improving our fitness as well as strength.

READ MORE:Adam Woodyatt weight loss: EastEnders star made easy change to slim

For complete beginners, I recommend starting in either a group training environment (like a (virtual) class for example) or with a personal trainer (online or in person).

When you have the advice of an instructor or coach you will learn how to train correctly and safely, this will enable you to perfect your technique and lower any injury risk.

The weights area in a gym training environment can look and feel a little intimidating to newbies, so following a routine even from your favourite Instagrammer or YouTuber will give you the courage to try something new and hit the weights.

It is also best to start of using small weights regularity and build up to heavier ones as this will cause less strain on the muscles.

Protein is also great for weight loss as it reduces the hunger hormone and boosts several satiety hormones.

Hayley continued: There are many forms of weight training you can try, from CrossFit to Body Pump classes (or virtual classes) it isnt a one size fits all form of training and is highly versatile.

Depending on your goal, I would always recommend incorporating some kind of weight training, even if youre a long-distance runner or a Yogi, the benefits of weight training can improve your performance in pretty much every sport.

Full body training can be a brilliant way to maintain strength all over if you only train two-three times a week, then adding in body part splits like lower body and upper body training can be a great way to target the individual muscles if you train more often like four-six times a week.

Research suggests that weight lifting burns almost just fat which can help target those stubborn areas which may carry more fat.

The expert explains how weight training is also a great way to develop coordination, attention and memory.

She explained: All of these improvements to the cognitive part of your brain will relay over to your everyday living, including your studying or working life there is so much more to weight training than just improving muscle mass!

Original post:
How to exercise to lose weight and build muscle at the same time - Daily Express


Nov 1

The Bariatric Experience Long Term (BELONG): Factors Related to Having Bariatric Surgery in a Large Integrated Healthcare System – DocWire News

This article was originally published here

Obes Surg. 2020 Oct 30. doi: 10.1007/s11695-020-05045-7. Online ahead of print.

ABSTRACT

PURPOSE: Bariatric surgery is the most effective treatment for severe obesity, but currently, only 1-2% of all eligible patients undergo surgery each year. This study examined which factors were associated with a patient receiving bariatric surgery after referral in a real-world healthcare setting.

MATERIALS AND METHODS: The current study used the baseline survey and electronic medical record (EMR) data from the Bariatric Experience Long Term (BELONG) study (n = 1975). Predictors of who did (n = 1680) and who did not (n = 295) have surgery were analyzed using multivariate logistic regression.

RESULTS: Participants (n = 1975; 42.4% response rate) were primarily women (84%) and either non-Hispanic Black or Hispanic (60%). In the fully adjusted multivariate model, the strongest predictors of having surgery were being a woman (OR = 3.17; 95% CI = 2.15, 4.68; p < .001) and losing at least 5% of their body weight in the year before surgery (OR = 3.16; 95% CI = 2.28, 4.38; p < .001). The strongest predictors of not having surgery were a BMI 50 kg/m2 (OR = .39; 95% CI = .27, .56; p < .001) and having a higher physical comorbidity burden (OR = .84; 95% CI = .75, .94; p = .004).

CONCLUSIONS: Practices such as 5-10% total weight loss before surgery and selection of patients with safer operative risk profiles (younger with lower comorbidity burden) may inadvertently contribute to under-utilization of bariatric surgery among some demographic subpopulations who could most benefit from this intervention.

PMID:33125675 | DOI:10.1007/s11695-020-05045-7

The rest is here:
The Bariatric Experience Long Term (BELONG): Factors Related to Having Bariatric Surgery in a Large Integrated Healthcare System - DocWire News


Nov 1

Savvy Senior: How to recognize and stop elder abuse in the COVID era – Huron Daily Tribune

Savvy Senior:How to recognize and stop elder abuse in the COVID era

Dear Savvy Senior,

Can you write a column on how to recognize elder abuse and what to do if you suspect it?

Concerned Relative

Dear Concerned,

Elder abuse is a big problem in the United States that has escalated during the COVID-19 pandemic. According to the National Council on Aging, as many as 5 million seniors are victims of abuse each year, but studies suggest this crime is significantly under-reported. Only 1-in-14 cases of elder abuse ever get reported to the authorities because victims are usually too afraid, too embarrassed, too helpless or too trusting to call for help.

The term elder abuse is defined as intentional or negligent acts by a caregiver or trusted individual that causes or can cause harm to a vulnerable senior. Elder abuse also comes in many different forms: emotional, psychological, physical or sexual abuse, abandonment, neglect and self-neglect, and financial exploitation.

Those most vulnerable are seniors that are ill, frail, disabled, socially isolated or mentally impaired due to dementia or Alzheimers disease.

Its also important to know that while elder abuse does happen in nursing homes and other long-term care facilities, the vast majority of incidents take place at home where the senior lives. And tragically, the abusers are most often their own family members (usually the victims adult child or spouse) or caregiver.

How to Recognize Abuse

So, how can you tell if an elderly relative or friend is being abused, and what can you do to help?

A change in general behavior is a universal warning sign that a problem exists. If you notice that your relative or friend has become very depressed, withdrawn or gets upset or agitated easily, you need to start asking questions. Here are some additional warning signs on the different types of elder abuse that can help you spot a possible problem.

Physical or sexual abuse: Suspicious bruises or other injuries that cant be explained. Sudden changes in behavior (upset, withdrawn, fearful). Broken eyeglasses. Caregivers refusal to allow visitors to see an elder alone.

Neglect or self-neglect: Weight loss, poor hygiene, unattended medical needs, and unsanitary, unsafe living conditions.

Emotional or psychological abuse: The senior is extremely upset, agitated, withdrawn, unresponsive, fearful or depressed, or demonstrates some other unusual behavior.

Financial exploitation: Missing money or valuables. Unexplained withdrawals from bank accounts, or transfers between accounts. Unauthorized use of credit, debit or ATM card. Unpaid bills despite available funds. Checks written as a loan or gift. Abrupt changes in a will or other documents.

For more tips on how to recognize the warning signs of abuse during the pandemic, see the National Center on Elder Abuse website at NCEA.acl.gov/Resources/COVID-19.aspx.

What to Do

The best ways to help stop elder abuse is to be in touch and keep the lines of communication open. If you suspect any type of abuse or neglect in your relatives or friends home, report it to your local protective services agency.

Adult Protective Services is the government agency responsible for investigating elder abuse cases and providing help and guidance. Call the Eldercare Locator at 800-677-1116 to get the agency contact number in your area or visit NCEA.acl.gov/Resources/State.aspx.

The agency will ask what you observed, who was involved, and who they can contact to learn more. You dont need to prove that abuse is occurring; it is up to the professional.

Or, to report suspected abuse in a nursing home or assisted living facility, call the local Long-Term Care Ombudsman see LTCombudsman.org for contact information.

If, however, you feel the person is in immediate danger, call 911 or the local police for immediate help.

Send your senior questions to: Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit SavvySenior.org. Jim Miller is a contributor to the NBC Today show and author of The Savvy Senior book.

See the original post:
Savvy Senior: How to recognize and stop elder abuse in the COVID era - Huron Daily Tribune


Nov 1

Female Care Team Understands the Unique Needs of Women – Prince William Living

By Dr. Havya Dave and Karen Holdsworth, NPProvided by Sentara Northern Virginia Medical Center

Women have particular health-care needs, which often means multiple appointments with different providers. But the female team of providers at Sentara Internal Medicine Physicians in Woodbridge has set out to give women an experience that meets their needs.

Havya Dave, M.D. and Karen Holdsworth, NP understand that women have different needs and many demands placed on them. The duo has worked to establish a practice where women can get much of their care in one location, at one visit.

Most people, but particularly women, talk more openly with their primary care provider since they have a rapport, says Holdsworth. Its easier for us to provide holistic care because we have the time to build a trusting relationship where people open up about their concerns.

We created a practice that allows us to do more for our female patients, says Holdsworth. Women are pulled in so many different directions. We make it easier for them to receive whatever services they need in a single visit, whenever possible. This approach promotes continuity of care because we see the big health picture.

This team of providers eliminates the burden of having to make multiple appointments in different places to take care of health needs.

The team sees females from ages 13 and up. In addition to typical primary care services, they offer:

Preventive gynecologic care can help identify and treat precancerous cells before problems start. The team offers Pap tests and pelvic exams as part of the annual exam. They also perform surgical removal of uterine polyps. And they provide biopsies of the uterine lining to help diagnose bleeding and other problems.

One of the most common concerns women have is related to menstruation, says Dr. Dave. We help women who experience every degree of bleeding, period pain and cycle-related mood swings.

The providers also support women who are pre- or postmenopausal. Holdsworth notes, We address all of the issues that come with menopause, so we can improve womens quality of life.

Our goal is to create an environment where women of all ages can talk about their sexual concerns or ask questions, says Dr. Dave. We offer judgment-free advice and provide contraception services that meet a womans specific situation.

The practice offers prevention and treatment services for sexually transmitted infections, plus contraceptive services, including:

Women who experience incontinence can get early care. The team helps women understand their options, counsels on Kegel exercises and prescribes medications. And they offer cleaning and replacement services for women who have a pessary.

Weight management isnt unique to women, but women think about and process weight concerns differently than men, says Holdsworth. We offer sustainable weight loss advice that includes nutrition and exercise counseling. We dont offer fad, get-thin-quick diets because we know they dont work long-term.

Our environment supports women, says Holdsworth. We want women to feel they arent alone and that their concerns are normal. When they feel supported, they are more at ease and have improved quality of life.

The providers believe that by helping women, theyre helping those around them. Women are the lifeblood of happy, healthy households. When we improve the quality of life for women, we help entire families function better, says Dr. Dave.

Both providers accept new patients at Sentara Internal Medicine Physicians, located at 2280 Opitz Blvd., Suite 250, Woodbridge. Make an appointment by calling 703-523-9750.

Original post:
Female Care Team Understands the Unique Needs of Women - Prince William Living


Nov 1

Focus on Fitness: There’s more to lifting weights than meets the eye – Plant City Observer

If youre not incorporating weight training into your workouts, you should consider working it in them now. You may thank yourself later.

Lifting weights isnt just about bulking up and building muscle mass. Its other benefits include improved posture, better sleep, gaining bone density, maintaining weight loss, boosting metabolism, lowering inflammation and staving off chronic disease, to name a few things on the laundry list of positives.

Ask the average person to design an effective fitness plan and a lot of them will immediately go to cardio: walking, running, swimming and using the gyms machines. And while these methods can be effective in burning calories, they may not do enough to build lean muscle capable of improving athletic performance and boosting the metabolism.

Thats why the most effective fitness plans need to include lifting weights and a commitment to strength training. It doesnt mean you have to pump 50-pound dumbbells or spend your whole trip to the gym at the weight machines, but it does mean there has to be some investment of your time and energy toward training with weights.

Lets take a look at the main reason to add weight training to your exercise regimen: it can add years to your life.

Thats because muscle mass plays an important part in determining how we age, and that increased muscle capacity can help us reduce our overall risk of death. In fact, as we age, the focus on losing fat or maintaining weight becomes progressively less important as we progress toward prioritizing keeping the muscle mass and strength we have.

We do so much to improve our overall health but we dont always think about how our exercise regimen affects our long term. For young and middle-aged people, the fitness goal is usually to look and feel better both today and in the near future (perhaps even decades down the road). But the 75-year-old version of you, the one enjoying retirement and spending time with the grandchildren, may be really pleased that the younger edition of you made a commitment to strength training and lifting weights.

Mike Gartz is a personal trainer who owns I Hate My Trainer at 117 E. Reynolds St. Plant City.

Related Stories

Here is the original post:
Focus on Fitness: There's more to lifting weights than meets the eye - Plant City Observer


Oct 30

Do Body Wraps Work for Weight Loss? Types and Effectiveness – Greatist

Honestly, whats the deal with body wraps? Do they really help you shed the pounds or belly fat? Are they the same as waist trainers? Are they even safe? So many questions provoked by endless Kardashian waist-snatching selfies and weight loss ads.

Body wraps 101

Unwrapping the truth about body wraps can be overwhelming. Here are the fast facts.

Do body wraps help you lose weight?

Nope. Any slimming is probably just temporary loss of water weight.

Are they safe?

Mostly, yes. But you should consider the risks of dehydration and restricted breathing. (More on that in a sec!)

Can I DIY body wraps at home?

Of course! Well dive into the DIY details and types of body wraps below.

Body wraps are noninvasive treatments touted for a variety of health, beauty, and general wellness benefits.

They typically involve applying a skin care mask or cream and then covering the area with a fabric or plastic wrap. Together, these elements are said to melt fat away while giving you perfectly taut skin, but they can come with some risks.

Find the right type of body wrap for you.

Picture super-spanx reminiscent of old-timey corsets. They come in tons of styles and fabrics, but they all focus on cinching your midsection into an hourglass-like figure.

Waist trainers claim to make your waist smaller by physically squeezing it in, but the results are temporary. Once the trainers off, your muscles will happily return to their natural shape.

PSA for the preggo peeps: There are lots of waist trainers and compression garments marketed toward pregnant women and new mommas. Research is still iffy on their effectiveness, so check with your doc before wrapping your changing belly.

Classic wraps are supposed to work by making you sweat off inches. Fans say that using a mask or cream with the binding boosts the effect by drawing out even more fluid and toxins.

In the past, folks used linen or muslin that had been coated to make the fabric less breathable. Today, DIYers prefer plastic wrap. Whatever the material, its usually ripped into strips to wrap around the treatment area belly, thighs, etc.

Many wrap products claim to help your body detox. Science shows that some compounds, like bentonite clay, can help detoxify your body by absorbing negatively charged ions and speeding up natural detox processes (like, erm, pooping).

But can it do all that through your skin? Thats up for debate.

Types of spa wraps

Get the DL on the most popular spa wraps.

The idea here is to encase your whole body in an impermeable sack that makes you sweat a whole hell of a lot. Yep, youll look and feel like a foil-wrapped baked potato.

These devices use hot air, infrared technology, or another heating element to get you cooking. Theyre supposed to work by making you sweat off excess weight and inches, but the weight loss effect is water weight not fat.

This is not an effective long-term weight loss strategy. A more reliable, and safer bet? Large cross-sectional studies have shown that health benefits such as maintaining healthy mental well-being and sleep habits can aid in long-term weight loss.

Note: Make sure to stay hydrated if youre using sauna therapy!

Wrap your brain around these stats:

Its no wonder folks are seeking fast weight loss solutions that work.

But are body wraps the answer? Probably not.

Research suggests that swaddling yourself in nonbreathable fabric can raise your body temp, but theres just no evidence to support long-term weight loss from body wrapping. In fact, the FDA has investigated several companies for making false claims about their body wraps.

Still, body wrapping might help you:

First, decide whether to wrap your entire body or just part of it. Partial wraps can be applied to just your thighs or belly, for example.

Next, follow the instructions for the specific body wrap youve chosen. The process will look something like this:

If youre on a budget or enjoy whipping up your own lotions and potions, youre in luck. There are millions of recipes on the interwebz for exfoliants and wrap masks and creams.

As for making your own strip wraps? You can literally go buy a roll of plastic wrap. At-home spa enthusiasts rave that its easier, cheaper, quicker, and more sanitary than cloth strips. Its also great at sealing in the mask-and-sweat goo.

There are a few risks to body wrapping. Follow these tips to stay safe:

Consider these nuggets of weight loss wisdom:

While you can give body wraps a go, there are def more effective, sustainable options for healthy weight loss.

Scientifically proven ways to lose weight include:

Body wrap treatments come with a list of wellness claims, including quick weight loss, but most experts agree theyre not a good option for weight management. You might shed water weight, but the result is a temporary appearance of a slimmer bod and extra-luscious skin.

Instead of looking for a fast weight loss fix, aim for a healthy-for-you weight. Stick with this tried-and-true formula for safe, meaningful weight loss and weight management:

Read the original:
Do Body Wraps Work for Weight Loss? Types and Effectiveness - Greatist


Oct 30

Impact Of Covid-19 on Weight Loss Drinks Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 – PRnews Leader

Overview for Weight Loss Drinks Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

The global Weight Loss Drinks market focuses on encompassing major statistical evidence for the Weight Loss Drinks industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Weight Loss Drinks study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Weight Loss Drinks industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Weight Loss Drinks market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Weight Loss Drinks report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Weight Loss Drinks market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Weight Loss Drinks Market report @ https://hongchunresearch.com/request-a-sample/53721

Key players in the global Weight Loss Drinks market covered in Chapter 4:, skinnyfit, LadyBoss, GNC, Renewlife, HUM, Cellucor, Liquid I.V, Kate Farms, Herbal Clean, BPI

In Chapter 11 and 13.3, on the basis of types, the Weight Loss Drinks market from 2015 to 2026 is primarily split into:, Diet manage, Meal replacement

In Chapter 12 and 13.4, on the basis of applications, the Weight Loss Drinks market from 2015 to 2026 covers:, Online, Offline

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

The Weight Loss Drinks market study further highlights the segmentation of the Weight Loss Drinks industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Weight Loss Drinks report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Weight Loss Drinks market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Weight Loss Drinks market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Weight Loss Drinks industry as it explores the competitive nature of the market complete with a regional analysis.

Check [emailprotected] https://hongchunresearch.com/check-discount/53721

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Weight Loss Drinks Market

Chapter Four: Players Profiles

Chapter Five: Global Weight Loss Drinks Market Analysis by Regions

Chapter Six: North America Weight Loss Drinks Market Analysis by Countries

Chapter Seven: Europe Weight Loss Drinks Market Analysis by Countries

Chapter Eight: Asia-Pacific Weight Loss Drinks Market Analysis by Countries

Chapter Nine: Middle East and Africa Weight Loss Drinks Market Analysis by Countries

Chapter Ten: South America Weight Loss Drinks Market Analysis by Countries

Chapter Eleven: Global Weight Loss Drinks Market Segment by Types

Chapter Twelve: Global Weight Loss Drinks Market Segment by Applications 12.1 Global Weight Loss Drinks Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Weight Loss Drinks Sales and Market Share by Applications (2015-2020) 12.1.2 Global Weight Loss Drinks Revenue and Market Share by Applications (2015-2020) 12.2 Online Sales, Revenue and Growth Rate (2015-2020) 12.3 Offline Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Weight Loss Drinks Market Forecast by Regions (2020-2026) continued

List of tablesList of Tables and Figures Table Global Weight Loss Drinks Market Size Growth Rate by Type (2020-2026) Figure Global Weight Loss Drinks Market Share by Type in 2019 & 2026 Figure Diet manage Features Figure Meal replacement Features Table Global Weight Loss Drinks Market Size Growth by Application (2020-2026) Figure Global Weight Loss Drinks Market Share by Application in 2019 & 2026 Figure Online Description Figure Offline Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Weight Loss Drinks Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Weight Loss Drinks Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Weight Loss Drinks Figure Production Process of Weight Loss Drinks Figure Manufacturing Cost Structure of Weight Loss Drinks Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table skinnyfit Profile Table skinnyfit Production, Value, Price, Gross Margin 2015-2020 Table LadyBoss Profile Table LadyBoss Production, Value, Price, Gross Margin 2015-2020 Table GNC Profile Table GNC Production, Value, Price, Gross Margin 2015-2020 Table Renewlife Profile Table Renewlife Production, Value, Price, Gross Margin 2015-2020 Table HUM Profile Table HUM Production, Value, Price, Gross Margin 2015-2020 Table Cellucor Profile Table Cellucor Production, Value, Price, Gross Margin 2015-2020 Table Liquid I.V Profile Table Liquid I.V Production, Value, Price, Gross Margin 2015-2020 Table Kate Farms Profile Table Kate Farms Production, Value, Price, Gross Margin 2015-2020 Table Herbal Clean Profile Table Herbal Clean Production, Value, Price, Gross Margin 2015-2020 Table BPI Profile Table BPI Production, Value, Price, Gross Margin 2015-2020 Figure Global Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Global Weight Loss Drinks Revenue ($) and Growth (2015-2020) Table Global Weight Loss Drinks Sales by Regions (2015-2020) Table Global Weight Loss Drinks Sales Market Share by Regions (2015-2020) Table Global Weight Loss Drinks Revenue ($) by Regions (2015-2020) Table Global Weight Loss Drinks Revenue Market Share by Regions (2015-2020) Table Global Weight Loss Drinks Revenue Market Share by Regions in 2015 Table Global Weight Loss Drinks Revenue Market Share by Regions in 2019 Figure North America Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Europe Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Asia-Pacific Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Middle East and Africa Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure South America Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure North America Weight Loss Drinks Revenue ($) and Growth (2015-2020) Table North America Weight Loss Drinks Sales by Countries (2015-2020) Table North America Weight Loss Drinks Sales Market Share by Countries (2015-2020) Figure North America Weight Loss Drinks Sales Market Share by Countries in 2015 Figure North America Weight Loss Drinks Sales Market Share by Countries in 2019 Table North America Weight Loss Drinks Revenue ($) by Countries (2015-2020) Table North America Weight Loss Drinks Revenue Market Share by Countries (2015-2020) Figure North America Weight Loss Drinks Revenue Market Share by Countries in 2015 Figure North America Weight Loss Drinks Revenue Market Share by Countries in 2019 Figure United States Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Canada Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Mexico Weight Loss Drinks Sales and Growth (2015-2020) Figure Europe Weight Loss Drinks Revenue ($) Growth (2015-2020) Table Europe Weight Loss Drinks Sales by Countries (2015-2020) Table Europe Weight Loss Drinks Sales Market Share by Countries (2015-2020) Figure Europe Weight Loss Drinks Sales Market Share by Countries in 2015 Figure Europe Weight Loss Drinks Sales Market Share by Countries in 2019 Table Europe Weight Loss Drinks Revenue ($) by Countries (2015-2020) Table Europe Weight Loss Drinks Revenue Market Share by Countries (2015-2020) Figure Europe Weight Loss Drinks Revenue Market Share by Countries in 2015 Figure Europe Weight Loss Drinks Revenue Market Share by Countries in 2019 Figure Germany Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure UK Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure France Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Italy Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Spain Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Russia Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Asia-Pacific Weight Loss Drinks Revenue ($) and Growth (2015-2020) Table Asia-Pacific Weight Loss Drinks Sales by Countries (2015-2020) Table Asia-Pacific Weight Loss Drinks Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Weight Loss Drinks Sales Market Share by Countries in 2015 Figure Asia-Pacific Weight Loss Drinks Sales Market Share by Countries in 2019 Table Asia-Pacific Weight Loss Drinks Revenue ($) by Countries (2015-2020) Table Asia-Pacific Weight Loss Drinks Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Weight Loss Drinks Revenue Market Share by Countries in 2015 Figure Asia-Pacific Weight Loss Drinks Revenue Market Share by Countries in 2019 Figure China Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Japan Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure South Korea Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Australia Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure India Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Southeast Asia Weight Loss Drinks Sales and Growth Rate (2015-2020) Figure Middle East and Africa Weight Loss Drinks Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Weight Loss Drinks :

HongChun Research, Weight Loss Drinks , Weight Loss Drinks market, Weight Loss Drinks industry, Weight Loss Drinks market size, Weight Loss Drinks market share, Weight Loss Drinks market Forecast, Weight Loss Drinks market Outlook, Weight Loss Drinks market projection, Weight Loss Drinks market analysis, Weight Loss Drinks market SWOT Analysis, Weight Loss Drinks market insights

See the article here:
Impact Of Covid-19 on Weight Loss Drinks Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - PRnews Leader


Oct 30

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology -…

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, announced today that results from two pivotal Phase 3 studies evaluating setmelanotide in proopiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity were published in The Lancet Diabetes & Endocrinology. As previously reported, data from the studies demonstrate that treatment with setmelanotide, the companys melanocortin-4 receptor (MC4R) agonist, led to statistically significant and clinically meaningful reductions of weight and hunger.

Results from Rhythms pivotal Phase 3 studies, which are the largest studies to date in POMC and LEPR deficiency obesities, provide evidence regarding the safety and efficacy of setmelanotide and we believe they validate its potential long-term use as a novel treatment for severe obesity and hyperphagia, said co-author Peter Khnen, M.D., Institute for Experimental Pediatric Endocrinology, Charit Universittsmedizin Berlin, Germany. It is important to recognize the signs of these rare genetic disorders because we may soon have a targeted treatment option available for the first time for obesity disorders caused by impairments of the MC4R pathway.

Rhythm initially reported positive topline data from the Phase 3 studies in August 2019 and subsequently presented updated data in a late-breaking research forum during the 37th Annual Meeting of The Obesity Society at ObesityWeek 2019.

Eight of 10 participants with POMC deficiency obesity (80%; P<0.0001 compared with historical data) and five of 11 participants with LEPR deficiency obesity (45%; P=0.0001 compared with historical data) achieved at least 10 percent weight loss at approximately one year. The mean percent change in most hunger score in participants aged 12 years and older was -27.1 percent (n=7; P=0.0005) in POMC deficiency obesity and -43.7 percent (n=7; P<0.0001) in LEPR deficiency obesity. Consistent with prior clinical experience, setmelanotide was generally well-tolerated in both trials. The most common adverse events were injection site reaction, skin hyperpigmentation, and nausea.

These results are significant because, as we know from natural history data, individuals living with POMC or LEPR deficiency obesity consistently experience substantial weight gain each year beginning in early childhood, and we would not expect any of these patients to be able to achieve 10 percent weight loss over the course of a year without continued treatment, said co-author Karine Clment, professor of nutrition at Piti-Salptrire hospital and Sorbonne University in Paris. These data and the significant unmet need to address the obesity and hyperphagia caused by rare genetic disorders of obesity underscore the importance of testing for genetic variants that may impair MC4R activation and lead to severe obesity.

In May 2020, Rhythm announced that the U.S. Food and Drug Administration (FDA) accepted the company's New Drug Application (NDA) for setmelanotide for the treatment of POMC deficiency obesity and LEPR deficiency obesity, granted Priority Review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 27, 2020. In July 2020, the Company announced the submission of its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the treatment of POMC deficiency obesity and LEPR deficiency obesity.

We are grateful to the authors and the investigators involved in our pivotal Phase 3 clinical trials for their continued partnership in advancing setmelanotide to address significant unmet needs facing people with rare genetic disorders of obesity, Murray Stewart, M.D., Chief Medical Officer of Rhythm, said.

The article is available online here: http://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30364-8/fulltext.To request a copy of the article, email medinfo@rhythmtx.com.

About SetmelanotideSetmelanotide is an investigational, melanocortin-4 receptor (MC4R) agonist. The MC4R is part of the key biological pathway that independently regulates hunger, caloric intake, and energy expenditure. Variants in genes may impair the function of the MC4R pathway, potentially leading to hyperphagia and early-onset, severe obesity. Rhythm is currently developing setmelanotide as a targeted therapy to potentially restore the function of an impaired MC4R pathway and, in so doing, potentially reduce hunger and weight in patients with rare genetic disorders of obesity. Currently, no pharmacologic therapies exist to treat these conditions.

The FDA has granted Breakthrough Therapy designation to setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4R pathway, which includes POMC deficiency obesity, LEPR deficiency obesity, Bardet-Biedl Syndrome (BBS) and Alstrm syndrome. The EMA has also granted PRIority MEdicines (PRIME) designation for setmelanotide for the treatment of obesity and the control of hunger associated with deficiency disorders of the MC4R pathway. Both the FDA and EMA have granted orphan drug status to setmelanotide for POMC and LEPR deficiency obesities. Rhythm is also evaluating setmelanotide for reduction in hunger and body weight in a pivotal Phase 3 trial in people living with BBS and Alstrm syndromes, with topline data from this trial expected in the fourth quarter of 2020 or early in the first quarter of 2021.

About Rhythm PharmaceuticalsRhythm is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm is leveraging the Rhythm Engine -- comprised of its Phase 2 basket study, TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of rare genetic disorders of obesity. For healthcare professionals, visit http://www.UNcommonObesity.com for more information. For patients and caregivers, visit http://www.LEADforRareObesity.com for more information. The company is based in Boston, MA.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our business strategy and plans, including regarding commercialization of setmelanotide; the potential, safety, efficacy, and regulatory and clinical progress of setmelanotide, including anticipated timing of data readouts and our expectations surrounding potential regulatory approvals and timing thereof. Statements using words such as expect, anticipate, believe, may, will and similar terms are also forward-looking statements. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the impact of our management transition, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, our liquidity and expenses, the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies, clinical trials and commercialization prospects, and general economic conditions, and other important factors discussed under the caption Risk Factors in our Quarterly Report on Form 10-Q for the quarterly period endedJune 30, 2020and our other filings with theSecurities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Corporate Contact:David ConnollyHead of Investor Relations and Corporate CommunicationsRhythm Pharmaceuticals, Inc.857-264-4280dconnolly@rhythmtx.com

Investor Contact:Hannah DeresiewiczStern Investor Relations, Inc.212-362-1200hannah.deresiewicz@sternir.com

Media Contact:Adam Daley Berry & Company Public Relations212-253-8881adaley@berrypr.com

See the article here:
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology -...


Oct 30

Weight Loss and Obesity Management Market Growing at a CAGR %: Analysis of Prevailing Industry Opportunities and Winning Manufacturers 2018-2028 – The…

A new report by XploreMR takes a deep dive into the Weight Loss and Obesity Management Market after conducting meticulous research, assessing each microscopic aspect of the market. The researches have connected the dots with minuscule details that shape into an intricate, immaculate yet elucidate study. The report presents a thoroughly scrutinized study of the Weight Loss and Obesity Management Market, leaving no stone unturned in offering market players a valuable and constructive tool that navigates them in the profitable path with the right set of objectives.

Following the methodology of Porters Five Forces analysis, the report emphasizes macro concepts such as the threat of new entries in the Weight Loss and Obesity Management Market, supplier power, threat of substitution, and buying power. Dwelling deeper into each of the factors, details about the competitive landscape, strategies of leading market players, and changes in the landscape, are also analyzed. In addition to competitive analysis, the researchers have also employed PESTEL analysis to study the impact of political, economic, social, technological, environmental, and legal factors on the keyword, thus leaving no loose ends.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/3751

The researchers have studied the factors that are expected to drive the growth of the Weight Loss and Obesity Management by creating revenue opportunities, directly and indirectly. Similarly, the emerging trends, both long-term and short-term, present factors that are likely to impact the markets growth and project the direction the whole market is moving. Economical, technological, or any other trend that could bestow opportunities, have been studied. Moreover, the researchers have expanded the analysis beyond growth prospects and analyzed the possible restraining factors to the growth of the Weight Loss and Obesity Management Market, thus enabling market players to foresee the likely challenges and emerge successful through the forecast period 2018-2028.

In addition to the macro-economic factors that drive the global market, the market divulges micro-economic factors, diving into each individual segment such as geographical, end-use segments, and products, among others, and studies each of the segments with respect to different geographies. The geography-specific insights paint a crystal clear picture of the growth of every individual segment studied in the report, thereby enabling regional market players to leverage the trends in the region.

The report assesses key players in the Weight Loss and Obesity Management Market, studying their services, strategies, landmarks, growth plans, and recent developments. By studying multiple organizations covering small, medium, and large players the report enables emerging players to equip themselves with knowledge of competition scenarios. The most critical aspect in the competitive landscape individual growth strategy is studied extensively by dwelling into the foregoing growth trajectory of the organization. Moreover, the study paints a picture of the individual standpoints of the players in the years to come, considering the drivers and trends.

To breakdown the vast study that spreads through geographies, products, and end-use segments, among other market-specific segments, the authors present CAGR (Compound Annual Growth Rate) of each segment throughout the years of forecast. CAGR is a simplistic representation of growth that clearly projects which segment registered the highest/least growth through the forecast period 2018-2028. Moreover, each segment is analyzed on the basis of volume and volume, also projected with year-on-year growth and CAGR.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/3751

Researchers also present production and consumption analysis, key findings, important suggestions and recommendations, and other aspects, thus offering a comprehensive picture of the Weight Loss and Obesity Management Market to bolster market players in planning their strategies in the years to come.

Important Questions Answered

Highlights of TOC:

Overview: Presents a broad overview of the Weight Loss and Obesity Management market, acting as a snapshot of the elaborate study that follows.

Market Dynamics: A straight-forward discussion about key drivers, restraints, challenges, trends, and opportunities of the Weight Loss and Obesity Management market.

Product Segments: Explores the market growth of the wide variety of products offered by organizations, and how they fare with end-users.

Application Segments: This section studies the key end-use applications that contribute to the market growth and the emerging opportunities to the Weight Loss and Obesity Management market.

Geographical Segments: Each regional market with a region-specific study of each segment- is carefully assessed for understanding its current and future growth scenarios.

Company Profiles: Leading and emerging players of the Weight Loss and Obesity Management Market are thoroughly profiled in the report based on their market share, market served, products, applications, regional growth, and other factors.

Get Full Report Access athttps://www.xploremr.com/cart/3751/SL

Why Do Companies Trust XMR?

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis

Contact us:

XploreMR

111 North Market Street, Suite 300,

San Jose, CA 95113, United States

Ph.No: +16692840108

E-mail id- [emailprotected]

Web: https://xploremr.com

See original here:
Weight Loss and Obesity Management Market Growing at a CAGR %: Analysis of Prevailing Industry Opportunities and Winning Manufacturers 2018-2028 - The...



Page 4«..3456..1020..»